RxDoctor Payments Data

Eduardo Viera, MD

Internal Medicine · Miami, FLNPI 1144273426

Payments from drug & device makers

$3,528,291in general payments, 2019–2025

Across 257 payments — averaging $13,729 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$3M
  • Astrazeneca UK Limited$158K
  • Sun Pharmaceutical Industries Inc.$137K
  • Chiesi USA, Inc.$112K
  • GSK$86K
  • Sanofi US Services Inc.$19K
  • plus $17K from 20 others

What the payments were for

  • Consulting fees$1,37841%
  • Travel & lodging$512%
  • Food & beverage$1,96258%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,528,291 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$4,444
Medicare patients
14
Services billed
69

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin218$230,720
OzempicSemaglutide212$211,209
FarxigaDapagliflozin Propanediol217$179,644
EliquisApixaban168$118,330
EntrestoSacubitril/Valsartan89$70,361
LinzessLinaclotide111$62,053
MounjaroTirzepatide51$59,024
JanuviaSitagliptin Phosphate62$48,708
CreonLipase/Protease/Amylase74$38,138
XareltoRivaroxaban56$32,112
JanumetSitagliptin Phos/Metformin Hcl38$24,683
Xigduo XrDapaglifloz Propaned/Metformin24$23,071
SymbicortBudesonide/Formoterol Fumarate100$22,542
Breo ElliptaFluticasone/Vilanterol54$21,880
ProliaDenosumab11$19,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Tradjenta$36$257,600263 claims
AstraZenecaFarxiga, Symbicort, Brilinta, Breztri Aerosphere$708$227,504359 claims
Novo NordiskOzempic$1,954$211,209212 claims
PfizerEliquis$107$118,330168 claims
AbbVieLinzess, Creon, Restasis$34$113,643206 claims
NovartisEntresto$57$70,36189 claims
Lilly USA, LLCMounjaro$65$59,02451 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta$86,346$41,04288 claims
Johnson & JohnsonXarelto$36$32,11256 claims
AmgenProlia$56$19,08911 claims
Astellas Pharma US IncMyrbetriq$98$17,23439 claims
Sanofi-aventis U.S. LLCMultaq$13$10,43613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →